Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Spectral Med Inc

Healthcare CA EDT

1.4CAD
-0.01(0.71%)

Last update at 2026-06-05T18:12:00Z

Day Range

1.371.42
LowHigh

52 Week Range

0.771.76
LowHigh

Fundamentals

  • Previous Close 1.41
  • Market Cap399.05M
  • Volume58280
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.04800M
  • Revenue TTM2.44M
  • Revenue Per Share TTM0.009
  • Gross Profit TTM 1.33M
  • Diluted EPS TTM-0.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -47.68900M -15.39500M -15.50700M -9.59300M -8.78500M
Minority interest - - - - -
Net income -47.69200M -15.40200M -15.66200M -11.29900M -8.94100M
Selling general administrative 11.73M 11.62M 4.83M 8.01M 9.43M
Selling and marketing expenses - - 6.47M - -
Gross profit -5.15600M 1.02M 0.66M 0.98M 1.22M
Reconciled depreciation 0.25M 0.25M 0.22M 0.27M 0.29M
Ebit -11.68500M -12.21800M -14.17300M -9.44000M -8.60100M
Ebitda -11.43500M -11.96700M -13.95500M -9.16800M -8.30700M
Depreciation and amortization 0.25M 0.25M 0.22M 0.27M 0.29M
Non operating income net other - - - - -
Operating income -11.68500M -11.99700M -11.42100M -9.44000M -8.60100M
Other operating expenses 14.13M 14.28M 13.02M 8.92M 10.56M
Interest expense 5.16M 3.18M 1.33M 0.10M 0.03M
Tax provision - - - - -
Interest income - - - - -
Net interest income 0.23M -3.17700M -1.33400M -0.10400M -0.02800M
Extraordinary items - -0.00700M -0.15500M -3.65300M -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.15M 1.71M 0.16M
Total revenue 2.44M 2.29M 1.60M 1.67M 2.05M
Total operating expenses 6.53M 13.02M 12.08M 8.23M 9.73M
Cost of revenue 7.60M 1.27M 0.94M 0.68M 0.83M
Total other income expense net -36.00400M -3.39800M -4.08600M -0.15300M -0.18400M
Discontinued operations - - - -3.65300M -3.65300M
Net income from continuing ops -47.68900M -15.39500M -15.50700M -9.59300M -8.78500M
Net income applicable to common shares - -15.40200M -15.66200M -11.25000M -8.78500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6.10M 5.32M 5.21M 12.00M 11.55M
Intangible assets 0.33M 0.17M 0.19M 0.21M 0.23M
Earning assets - - - - -
Other current assets 0.64M - 0.62M 0.28M 0.97M
Total liab 75.82M 32.87M 21.76M 14.52M 7.47M
Total stockholder equity -69.72200M -27.54500M -16.54900M -2.52300M 4.08M
Deferred long term liab - - - - -
Other current liab 47.67M 9.74M 7.53M 1.52M 1.08M
Common stock 95.93M - 87.06M 87.05M 84.36M
Capital stock 95.93M 90.57M 87.06M 87.05M 84.36M
Retained earnings -188.53100M -140.83900M -125.43700M -109.74400M -98.49400M
Other liab - - - 4.01M 4.68M
Good will - - - - -
Other assets - - - - -
Cash 4.07M 2.99M 2.95M 8.41M 8.89M
Cash and equivalents - - - - -
Total current liabilities 66.27M 27.45M 10.24M 3.96M 2.30M
Current deferred revenue 0.69M - 0.73M 0.70M 0.69M
Net debt 17.02M 11.44M 5.61M -1.76900M -8.30800M
Short term debt 16.57M - 0.39M 0.10M 0.09M
Short long term debt 16.43M 14.43M 0.26M - -
Short long term debt total 21.09M - 8.56M 6.64M 0.58M
Other stockholder equity 10.22M - 8.92M 20.17M 18.22M
Property plant equipment - - - 0.70M 1.06M
Total current assets 5.29M 4.46M 4.12M 10.09M 10.26M
Long term investments - 0.00000M 0.00000M 1.00M -
Net tangible assets - - - -2.73400M 3.85M
Short term investments - - 0.61M - -
Net receivables 0.20M 0.30M 0.19M 1.06M 0.20M
Long term debt 4.75M - 7.68M 6.13M -
Inventory 0.38M 0.23M 0.37M 0.34M 0.29M
Accounts payable 1.34M 0.99M 1.60M 1.65M 0.44M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 12.66M - 12.91M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.81M 0.86M 1.09M 1.91M 1.29M
Capital lease obligations 0.37M 0.50M 0.62M 0.52M 0.58M
Long term debt total - - - 6.55M 0.49M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02700M -0.18500M -0.03300M -0.32500M
Change to liabilities - - - 0.96M -1.27500M
Total cashflows from investing activities -0.19500M -0.02700M -0.18500M -0.03300M -0.32500M
Net borrowings 9.51M 9.74M 3.93M 6.71M -0.11300M
Total cash from financing activities 12.91M 8.88M 5.44M 9.48M 12.16M
Change to operating activities - - - 0.60M -0.48600M
Net income -47.69200M -15.39500M -15.66200M -11.25000M -8.78500M
Change in cash 1.08M 0.04M -5.46200M -0.47600M 3.08M
Begin period cash flow 2.99M 2.95M 8.41M 8.89M 5.81M
End period cash flow 4.07M 2.99M 2.95M 8.41M 8.89M
Total cash from operating activities -11.63200M -8.81800M -10.72100M -9.92800M -8.70100M
Issuance of capital stock - - 0.00000M 4.03M 10.00M
Depreciation 0.25M 0.25M 0.22M 0.27M 0.29M
Other cashflows from investing activities - - - 0.00000M 0.16M
Dividends paid 0.00000M 0.00000M 0.00000M - -
Change to inventory -0.14800M 0.14M -0.02600M -0.04700M -0.05100M
Change to account receivables 0.25M -0.26500M 0.87M -0.85100M 0.06M
Sale purchase of stock - 1.15M - 4.11M 13.41M
Other cashflows from financing activities -0.15500M -2.01500M 1.51M 5.55M 2.28M
Change to netincome - - - 0.39M 1.55M
Capital expenditures 0.20M 0.03M 0.18M 0.03M 0.48M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.18900M 1.01M -0.40600M 0.66M -1.75700M
Stock based compensation 2.12M 1.68M 1.49M 1.20M 1.26M
Other non cash items -11.69300M 3.64M 3.64M -0.80600M 0.29M
Free cash flow -9.71900M -8.84500M -10.90600M -9.96100M -9.18400M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EDT
Spectral Med Inc		 -0.01 0.71% 1.40 - 99.01 163.41 52.98 171.77 -7.5083

Reports Covered

Stock Research & News

View All

Profile

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Spectral Med Inc

135 The West Mall, Toronto, ON, Canada, M9C 1C2

Key Executives

Name Title Year Born
Mr. Christopher Seto CEO & Director NA
Dr. John A. Kellum M.D. Chief Medical Officer NA
Ms. Debra-Anne M. Foster B.Sc., RN, CCRC VP of Clinical Devel. NA
Mr. Blair McInnis Chief Financial Officer NA
Mr. Sam Amory Pres of Dialco Medical Inc. NA
Mr. Christopher Seto CEO, CFO & Director NA
Mr. Christopher Seto CEO, Interim CFO & Director NA
Prof. John A. Kellum M.D. Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.